Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 431

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1A
Chunk 431
---
 programs from August 2018 through December 2023. During his
tenure at HLB, Mr. Jee led the firm’s global IR, M&As and strategic investment activities. Prior to his careers in the
biopharmaceutical industry, Mr. Jee has spent more than 15 years serving with brokerage and investment banking firms, mostly
representing their European offices and providing services to the European and global fund clients investing in Korean equities market.
Those engagements include Korea Investment Securities Europe (London), Daewoo Securities Europe (London), and Hyundai Securities Europe
(London and Seoul) between July 2002 and January 2018. Mr. Jee has started his finance career as an Analyst and Portfolio
Manager at Scudder Kemper and Schroders based in Seoul, Korea serving from 1998 to 2002. Mr. Jee has received his B.A. in Business
Administration from the Korea University in 1994. Mr. Jee is well qualified to serve as a Director because of his well-balanced career
between finance and biopharmaceutical industries, especially leading M&A transactions while serving from executive positions with
his previous employer.

96

Dr. Joong Myung Cho became a Director of the Company upon the
Closing of the Business Combination. Dr. Cho has been Chairman and CEO of CG Pharmaceuticals, Inc. since October 2008 and previously
served as Chairman and CEO of Hwail Pharmaceuticals Co. Ltd. from August 2013 to December 2022. Dr. Cho is the founder
of Crystal Genomics and the former Chairman & President (July 2000 to March 2023). He has over 40 years of experience
in biopharmaceutical industry covering from discovery of novel pharmaceuticals through R&D and commercialization. Dr. Cho has
previously served as the executive Senior Vice President and Director of R&D Biotech Research Institute at LG Life Science (formerly
LG Chem.) from 1984 to 2000. During his tenure, biopharmaceutical R&D at LG became the leading life science company in Korea where
it grew from just a few research scientists to several hundred prior to his departure. He has successfully introduced 10 different recombinant
products such as growth hormones of human, bovine, and porcine, hepatitis B vaccine, interferon alpha and gamma, GM-CSF, EPO, etc. Moreover,
four